Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects - PubMed (original) (raw)

Clinical Trial

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects

J P Frias et al. Diabetes Care. 2000 Jan.

Abstract

Objective: To characterize metabolic effects of troglitazone in type 2 diabetic, obese, and lean subjects, and examine the effects of troglitazone 2-3 weeks after discontinuation.

Research design and methods: Nine type 2 diabetic, nine obese, and nine lean subjects underwent baseline metabolic studies including an 8-h meal-tolerance test (MTT) and a 5-h glucose clamp. Subjects then received troglitazone (600 mg/day) for 12 weeks and subsequently had repeat metabolic studies. Diabetic subjects remained off hypoglycemic agents for 2-3 weeks and then underwent a 5-h glucose clamp.

Results: In diabetic subjects, fasting plasma glucose was reduced (P<0.05) and insulin-stimulated glucose disposal (Rd) was enhanced by treatment (P<0.02). The area under the MTT 8-h plasma glucose curve declined with therapy (P<0.001), and its change was positively correlated with the improvement in Rd (r = 0.75, P<0.05). There was also a positive correlation between the change in fasting hepatic glucose output (HGO) and the change in fasting plasma glucose with treatment (r = 0.92, P<0.001). Discontinuation of therapy for 2-3 weeks did not significantly affect fasting plasma glucose or insulin-stimulated glucose Rd. In obese subjects, insulin-stimulated glucose Rd improved with therapy (P<0.001), allowing for maintenance of euglycemia by lower plasma insulin concentrations (P<0.05). In lean subjects, an increase in fasting HGO (P<0.001) and glucose clearance (P<0.01) was observed.

Conclusions: Troglitazone lowers fasting and postprandial plasma glucose in type 2 diabetes by affecting both fasting HGO and peripheral insulin sensitivity. Its effects are evident 2-3 weeks after discontinuation. In obese subjects, its insulin sensitizing effects suggest a role for its use in the primary prevention of type 2 diabetes.

PubMed Disclaimer

Cited by

Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states.
Greig FH, Nixon GF. Greig FH, et al. Pharmacol Ther. 2014 Sep;143(3):265-74. doi: 10.1016/j.pharmthera.2014.03.006. Epub 2014 Mar 20. Pharmacol Ther. 2014. PMID: 24657708 Free PMC article. Review.
The antidiabetic drug troglitazone protects against PrP (106‑126)‑induced neurotoxicity via the PPARγ‑autophagy pathway in neuronal cells.
Moon JH, Hong JM, Park SY. Moon JH, et al. Mol Med Rep. 2021 Jun;23(6):430. doi: 10.3892/mmr.2021.12069. Epub 2021 Apr 13. Mol Med Rep. 2021. PMID: 33846779 Free PMC article.
PPAR gamma and human metabolic disease.
Semple RK, Chatterjee VK, O'Rahilly S. Semple RK, et al. J Clin Invest. 2006 Mar;116(3):581-9. doi: 10.1172/JCI28003. J Clin Invest. 2006. PMID: 16511590 Free PMC article. Review.
Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes.
Reeds DN, Patterson BW, Okunade A, Holloszy JO, Polonsky KS, Klein S. Reeds DN, et al. Diabetes Care. 2011 May;34(5):1071-6. doi: 10.2337/dc10-2299. Epub 2011 Mar 16. Diabetes Care. 2011. PMID: 21411505 Free PMC article. Clinical Trial.
Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.
Shankar SS, Shankar RR, Railkar RA, Beals CR, Steinberg HO, Kelley DE. Shankar SS, et al. Curr Ther Res Clin Exp. 2015 Aug 14;77:83-9. doi: 10.1016/j.curtheres.2015.08.001. eCollection 2015 Dec. Curr Ther Res Clin Exp. 2015. PMID: 26543510 Free PMC article.

Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects - PubMed (original) (raw)